Equity / Investment · Africa · Announced 8 Jul 2026
Natco Pharma → Adcock Ingram
Natco Pharma's board approved about US$260 million for South Africa: raising its Adcock Ingram stake from 35.75% to 49% at ZAR 92.50 a share and injecting about US$146 million into its local subsidiary.
Parties: Natco Pharma (India) → Adcock Ingram (South Africa)
- Deal type
- Equity / Investment
- Value
- $260m
- Territory
- South Africa and wider African markets
- Therapeutic area
- Multi-therapy
- Asset
- Adcock Ingram shares
- Announced
- 8 Jul 2026
Our analysis
Why this matters
On 8 July 2026, Natco Pharma's board approved buying 19,618,825 more shares in JSE-listed Adcock Ingram at ZAR 92.50 a share (about ZAR 1.81 billion, roughly US$112 million), lifting its stake from 35.75% to 49%. It also approved investing up to INR 1,400 crore (about US$146 million) in its wholly owned subsidiary Natco Pharma South Africa. The combined commitment is about INR 25 billion (US$260 million). Closing was expected by the end of July 2026, subject to regulatory approvals.
Natco reports that Adcock Ingram generated US$423 million in revenue and about US$59 million in EBITDA in the nine months to 31 March 2026.
The full analysis is free to read with a work email on this page.
Source: Ecofin Agency